The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Emerging lymphoma therapies: bispecific antibodies and CAR T-cells
Stephen Opat, FRACP, FRCPA, MBBS, Monash University, Melbourne, Australia, shares his thoughts on emerging therapies for lymphomas that were presented at ASH 2020. Bispecific antibodies and CAR T-cell therapies have gained traction in early phase trials and are beginning to show promising efficacy results in both low- and high-grade malignancies. New challenges will emerge as to how best to optimize these therapies in the clinical setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research payments to institution: Beigene
